Autophagy is a central regulator of cell survival. It displays both anti-and pro-death roles that are decisive in the maintenance of cell homeostasis. Initially described in several eukaryotic cellular models as being induced under nutrient stress favouring survival by energy supply, autophagy was found later to display other decisive physiological roles, especially in the immune system. Thus, it is involved in antigen presentation and lymphocyte differentiation as well as in the balance regulating survival/death and activation of lymphocytes. Autophagy therefore appears to be central in the regulation of inflammation. The observation that autophagy is deregulated in systemic lupus erythematosus is recent. This discovery revives the programme dealing with the design and development of pharmacological autophagy regulators in the therapeutic context of lupus, a debilitating autoimmune disease that affects several million people in the world. A large number of molecules that positively and negatively regulate autophagy have been described, most of them with therapeutic indications in cancer and infection. Only a few, however, are effectively potent activators or inhibitors endowed with experimentally demonstrated selective properties. In this review article, we highlight the most relevant ones and summarize what we know regarding their mechanism of action. We emphasize the link between pharmacological regulators of autophagy and inducers or inhibitors of lupus disease and discuss the fundamental and pharmacological/therapeutic interest of this functional interplay.
AbbreviationsCMA, chaperone-mediated autophagy; CQ/HCQ, chloroquine/hydroxychloroquine; HSPA8/HSC70, heat shock cognate protein of 70 kDa; LAP, LC3-associated phagocytosis; LC3, microtubule-associated protein light chain 3; MHC-I/II, MHC class I or MHC class II; mTOR, mammalian target of rapamycin; PRR, pattern recognition receptors; SLE, systemic lupus erythematosus
TLR 9 RapamycinThis Table lists the protein targets and ligands in this article which are hyperlinked to corresponding entries in http:// www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013a).
Autophagy and its implication in human diseasesAutophagy is a catabolic process related to lysosomal degradation. Opposed to heterophagy, which implies degradation of substrates from outside the cell, autophagy catabolizes the cytoplasmic content. There are three main pathways involved in autophagy. The first one, called microautophagy, involves the direct engulfment of cytosolic material into the lysosome. Its core molecular machinery and regulation as well as its possible implication in human diseases are still poorly understood. In this review, we will focus the first part of our comments on the two other types of autophagy, namely, macroautophagy and chaperone-mediated autophagy (CMA). Historically, the term 'autophagy' was proposed by Christian De Duve in the ...